2nd Quarter - Report

NVG, LLC for PFIZER INC.

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Prescription drug coverage and payment policies; Medical innovation issues.

LobbyistCovered position, as disclosed
LISA GERMAN FOSTER —
ANDREA LARUE —
EDEN SHIFERAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual property, data exclusivity and patent eligibility, generally; CREATES Act of 2019 (S.340)/(H.R.965); Preserve Access to Affordable Generics and Biosimilars Act (S.64)/(H.R.2375); Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S.1224)/(H.R.2374); Prescription Pricing for People Act of 2019 (S.1227)/(H.R.2376); Affordable Prescriptions for Patients Act of 2019 (S.1416).

LobbyistCovered position, as disclosed
ANDREA LARUE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2376 (116th), H.R. 965 (116th), S. 340 (116th), H.R. 2374 (116th), S. 1224 (116th), S. 1416 (116th), H.R. 2375 (116th), S. 64 (116th), S. 1227 (116th)

Budget/Appropriations BUD

Childhood vaccination coverage disparities under Medicaid and CHIP, biosimilars, and non-opioid treatments in the House and Senate FY 2020 LHHS Appropriations bill.

LobbyistCovered position, as disclosed
IRENE BUENO —
LISA GERMAN FOSTER —
ANDREA LARUE —
JANE LOEWENSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.